With a new $30 million credit line, Raleigh pharma eyes FDA submission

A Triangle drugmaker has secured another $30 million in credit that its executives say will give it additional flexibility as it steams ahead towards approval of its main drug – saying that currently secured capital will be enough to keep it running through submission to the FDA.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.